Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D017320:HIV Protease Inhibitors; D007211:Indoles; D000077340:Fluvastatin